LEK FARMACEVTSKA DRUŽBA D.D.
|
Company: |
LEK FARMACEVTSKA DRUŽBA D.D.
|
Address: |
Verovškova ulica 57, 1526 Ljubljana
|
Google maps
|
Municipality: |
Ljubljana
|
Region: |
Central Slovenia (Osrednjeslovenska)
|
Contacts: |
00386 15802111
http://www.lek.si Robert Ljoljo
|
Company management: |
President of the Management Board: Robert Ljoljo Member of the Board: Andrej Pardo Member of the Board: Ksenija Butenko Černe Member of the Board: Marjan Novak Member of the Board: Raul Napoleon Intriago Lombeida Member of the Board: Uroš Urleb Member of the Board: Andreja Bucik Primožič
|
Extract of management responsible for a company's business operations abroad: |
Katja Razinger,
|
Registration number: |
1732811
|
Tax number: |
87916452
|
Organisational form: |
Joint Stock Company
|
Source of capital: |
Foreign
|
Inter-company connections: |
Parent company: Novartis AG, Lichtstrasse 35, 4056 Basel, Switzerland Subsidiary: Čistilna naprava Lendava d.o.o., Lendavska c. 30, 9220 Lendava - Lendva, Slovenia Subsidiary: Sandoz d.d., Verovškova 57, 1000 LJUBLJANA, Slovenia
|
Number of employees: |
4077
|
Size of company: |
Large
|
Income: |
1.649.043.301,00 €
|
Exports share in income: |
95,00 %
|
Tradition since: |
1946
|
Total equity: |
776.868.184,00 €
|
Total assets: |
1.148.917.859,00 €
|
Representation of third party's trade marks and companies: |
Sandoz: distribution of Sandoz products
|
Extract of target regions and countries where a company exports: |
Albania Algeria Argentina Armenia Australia Austria Azerbaijan Bangladesh Belarus Belgium Bosnia and Herzegovina Brazil Bulgaria Canada Chile China Colombia Croatia Czech Republic Denmark Ecuador Egypt Estonia Finland France Georgia Germany Ghana Greece Guatemala Hong Kong Special Administrative Region of China Hungary Iceland India Indonesia Iran (Islamic Republic of) Ireland Israel Italy Japan Jordan Kazakhstan Kosovo Kyrgyzstan Latvia Lebanon Lithuania Malaysia Mexico Mongolia Montenegro Morocco Netherlands New Zealand Niger Nigeria North Macedonia Norway Pakistan Panama Philippines Poland Portugal Republic of Korea Republic of Moldova Republic of South Africa Romania Russian Federation Saudi Arabia Serbia Singapore Slovakia Southern Africa Spain Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Thailand Tunisia Türkiye Turkmenistan Ukraine United Arab Emirates United Kingdom United States Uzbekistan Viet Nam
|
Description of company: |
Lek is one of the key pillars of the second-largest generic pharmaceutical company globally. Its role within Sandoz is to act as: a leading global development center for technologically demanding products and technologies; a key global manufacturing center for active pharmaceutical ingredients and medicines; a competence center for the development of vertically integrated products; a Sandoz competence center in the field of development and manufacturing of biosimilar active ingredients and products; a supply center for the markets of Central and Eastern Europe (CEE), South East Europe (SEE) and the Commonwealth of Independent States (CIS), and is responsible for marketing and sales of Sandoz products on the Slovenian market. For further information, please visit www.lek.si.
|
Description of products and services: |
Lek is one of key pillars of the second-largest generic pharmaceutical company globally. Its role within Sandoz is to act as: a leading global development center for products and technologies; a global manufacturing center for active pharmaceutical ingredients and medicines; a competence center for the development of vertically integrated products; a Sandoz competence center in the field of development and manufacturing of biosimilar products; and, a supply center for the markets of Central and Eastern Europe (CEE), South East Europe (SEE) and Commonwealth of Independent States (CIS), and it is responsible for sales on the Slovenian market. For further information please visit http://www.lek.si/eng/.
|
Keywords: |
Market keywords 05003005 Drug delivery and other equipment
06001015 Pharmaceutical Products / Drugs
|
Classification of company: |
Main activity in accordance with the NACE classification 21.200 Manufacture of pharmaceutical preparations
Activities in accordance with the CPA classification 21.10.10 Salicylic acid, O-acetylsalicylic acid, their salts and esters
|
Certificates: |
ECO-Management and Audit Scheme (EMAS) Responsible care
|
Field of activity: |
Chemical and Rubber Healthcare and Medical Industry
|
Credit rating information: |
|
Information on the presentation card companies are obtained from surveys. Financial data are for the financial year 2023, last update 22.05.2024. |
Last data update 07.10.2024. |